STOCK TITAN

Nutriband - NTRBW STOCK NEWS

Welcome to our dedicated page for Nutriband news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.

Overview of Nutriband Inc.

Nutriband Inc. (NASDAQ: NTRB, NASDAQ: NTRBW) is a U.S.-based pharmaceutical company headquartered in Oviedo, Florida. The company specializes in the development of innovative transdermal drug delivery systems, with a primary focus on addressing the global opioid crisis through its proprietary AVERSA™ abuse-deterrent technology. This technology is designed to incorporate aversive agents into transdermal patches to prevent the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, such as opioids.

Core Technology: AVERSA™

The cornerstone of Nutriband’s operations is its patented AVERSA™ technology, which employs a proprietary aversive agent coating to deter oral abuse and accidental exposure. This innovation is particularly significant for transdermal drugs like fentanyl, which carry a high risk of misuse. The AVERSA™ platform has broad applications and can be integrated into various transdermal patches, enhancing the safety profile of essential medications while ensuring accessibility for patients in need.

Key Product: AVERSA™ Fentanyl

The company’s lead product under development is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system. This product aims to be the world’s first abuse-deterrent opioid patch, addressing the dual challenges of opioid misuse and accidental exposure. AVERSA™ Fentanyl is being developed in collaboration with Kindeva Drug Delivery, a leading global contract development and manufacturing organization. The product is advancing through the U.S. FDA’s streamlined 505(b)(2) NDA regulatory pathway, which requires minimal clinical trials, potentially accelerating its time to market.

Intellectual Property and Global Reach

Nutriband’s AVERSA™ technology is protected by an extensive international intellectual property portfolio, with patents issued in 46 countries, including the United States, Europe, Japan, Korea, Russia, China, Canada, and Australia. This robust patent coverage positions the company to commercialize its technology on a global scale, ensuring competitive advantages in major pharmaceutical markets.

Revenue Streams and Market Presence

In addition to its pharmaceutical innovations, Nutriband generates revenue through its wholly-owned subsidiary, Pocono Pharma, which offers contract manufacturing services. The subsidiary specializes in kinesiology tape and other consumer transdermal products, supplying major retail chains such as Target, Walmart, Walgreens, and CVS. This diversified revenue model strengthens the company’s financial foundation while supporting its core R&D initiatives.

Strategic Collaborations

Nutriband has established strategic partnerships to advance its product pipeline. Its collaboration with Kindeva Drug Delivery ensures the scalability and commercial manufacturing capabilities required for AVERSA™ Fentanyl. Additionally, the company has licensed the use of Bitrex®, the world’s most bitter substance, as an aversive agent in its abuse-deterrent patches, further enhancing the effectiveness of its technology.

Market Significance

By addressing critical issues such as opioid misuse and accidental exposure, Nutriband positions itself as a key player in the abuse-deterrent pharmaceutical segment. The global market for such technologies is growing, driven by increasing regulatory focus on opioid safety and the need for innovative solutions to combat the opioid crisis. Nutriband’s AVERSA™ technology not only meets these demands but also sets a new standard for safety in transdermal drug delivery.

Conclusion

Nutriband Inc. is at the forefront of pharmaceutical innovation, leveraging its AVERSA™ technology to enhance patient safety and address pressing public health challenges. With its strong intellectual property portfolio, strategic collaborations, and diversified revenue streams, the company is well-positioned to make a significant impact in the pharmaceutical industry, particularly in the realm of abuse-deterrent drug delivery systems.

Rhea-AI Summary
Nutriband Inc. CEO Gareth Sheridan published a letter to shareholders outlining the company's achievements in 2023 and targets for 2024. The company made significant strides in developing transdermal pharmaceutical products, securing new IP, and signing a commercial development and clinical supply agreement with Kindeva Drug Delivery for AVERSA Fentanyl, estimated to potentially reach peak annual sales of $80M - $200M. The company also reported strong revenue growth in 2023 and aims to expand its revenue opportunities through marketing initiatives and new product launches in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.94%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. (NTRB) announced a commercial development and clinical supply agreement for their lead product, Aversa™ Fentanyl, with Kindeva Drug Delivery. The agreement aims to support a New Drug Application (NDA) with the FDA, replacing a previous feasibility agreement. Aversa™ Fentanyl is estimated to have the potential to reach peak annual US sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Nutriband Inc. (NTRB) launches Heating and Cooling Kinesiology Tape under AI Tape brand, offering pain-relieving ingredients for temporary relief of minor aches and pains. The product is the second launch this year, manufactured in the USA at Nutriband's facility in North Carolina, and available for purchase on Amazon and Activeintell.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.63%
Tags
AI
Rhea-AI Summary
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announces supplier agreement with KT Tape, a market leading kinesiology tape company, for a new line of specialized KT tape. The agreement showcases Nutriband's manufacturing capabilities and positions the company to develop innovative new product technologies with one of the world's largest brands, KT Tape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Nutriband completes market assessment and commercialization strategy for Aversa Buprenorphine transdermal system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Nutriband Inc. expands patent portfolio for AVERSA™ transdermal abuse deterrent technology, potentially reaching peak annual U.S. sales of $80M - $200M.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.93%
Tags
none
Rhea-AI Summary
Nutriband Inc. has been shortlisted for 5 awards at the Pharma Industry Awards 2023, recognizing their innovative development of AVERSA abuse-deterrent transdermal technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.86%
Tags
none
-
Rhea-AI Summary
Nutriband Inc. reports a 48% increase in Q2 2023 revenues compared to Q2 2022, with quarterly revenue of $655,928. Stockholders' equity is $6.9 million as of July 31, 2023. The launch of AI Tape brand and partnership with Donovan McNabb as brand ambassador are seen as positive milestones for the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nutriband engages Donovan McNabb as brand ambassador for AI Tape, targeting the $236M Elastic Therapeutic Tape market. McNabb's reputation as a pro athlete will deliver exposure and value to the brand. Global market expected to grow to $733.21M by 2033 with a CAGR of 12.0%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Rhea-AI Summary
Nutriband Inc. announces the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape, now available for purchase on Amazon and Activeintell.com. AI Tape combines traditional benefits of kinesiology tape with soothing and therapeutic ingredients. Nutriband CEO, Gareth Sheridan, expresses excitement for the launch of the brand, targeting the consumer market. AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
AI

FAQ

What is the current stock price of Nutriband (NTRBW)?

The current stock price of Nutriband (NTRBW) is $2.26 as of March 3, 2025.

What does Nutriband Inc. specialize in?

Nutriband Inc. specializes in transdermal drug delivery systems, focusing on abuse-deterrent technologies like its proprietary AVERSA™ platform.

What is AVERSA™ technology?

AVERSA™ is Nutriband’s patented technology that incorporates aversive agents into transdermal patches to deter abuse, misuse, and accidental exposure of drugs with high abuse potential.

What is Nutriband’s lead product?

Nutriband’s lead product is AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal patch designed to address opioid misuse and accidental exposure.

Where is Nutriband’s technology patented?

Nutriband’s AVERSA™ technology is patented in 46 countries, including the United States, Europe, Japan, Korea, Russia, and China.

How does Nutriband generate revenue?

Nutriband generates revenue through its pharmaceutical developments and contract manufacturing services offered by its subsidiary, Pocono Pharma.

Who are Nutriband’s strategic partners?

Nutriband collaborates with Kindeva Drug Delivery for manufacturing and has licensed Bitrex® as an aversive agent for its abuse-deterrent patches.

What challenges does Nutriband face?

Challenges include navigating regulatory pathways for FDA approval, securing funding for product development, and differentiating from competitors in the abuse-deterrent market.

What makes Nutriband unique in the pharmaceutical industry?

Nutriband’s focus on abuse-deterrent transdermal technology and its robust patent portfolio make it a unique player in addressing opioid safety and public health challenges.
Nutriband

Nasdaq:NTRBW

NTRBW Rankings

NTRBW Stock Data

11.11M
Biotechnology
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ORLANDO